Literature DB >> 12930442

Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model.

T Zellweger1, S Kiyama, K Chi, H Miyake, H Adomat, K Skov, M E Gleave.   

Abstract

OBJECTIVE: To evaluate the effect of clusterin overexpression on radiation-induced tumour growth rates and apoptosis in human prostate LNCaP cells, as prostate cancer cells are relatively resistant to radiation-induced apoptosis and local recurrences are common, but overexpression of the anti-apoptotic protein clusterin can accelerate progression to androgen-independence and to confer a chemoresistant phenotype in various prostate cancer models.
MATERIALS AND METHODS: Western blot analysis and immunohistochemistry were used to compare clusterin expression levels in parental (P) and clusterin-transfected (T) LNCaP cells in vitro and in vivo. The effects of radiation on clusterin-expression in both parental LNCaP/P and clusterin-transfected LNCaP/T tumours were analysed by Northern blot analysis. The cellular response to radiation was determined up to 3 weeks after irradiation using tetrazolium and re-growth assays, and cell-cycle analysis by flow cytometry.
RESULTS: Clusterin mRNA expression increased from undetectable to low levels in LNCaP/P tumours after radiation and more than three-fold in LNCaP/T tumours. Clusterin overexpression decreased the radiosensitivity in a time-dependent manner, reducing the extent of growth arrest and apoptosis by up to 54%. Re-growth assays showed that the improved survival rates of LNCaP/T cells after radiation did not change after 3 days, remaining constant over 3 weeks.
CONCLUSIONS: These results identify clusterin as a promoter of cell survival that may help mediate resistance to radiation-induced apoptosis. Furthermore, clusterin overexpression seems to provide an extended protection against radiation-induced cell cycle arrest and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930442     DOI: 10.1046/j.1464-410x.2003.04349.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

Review 2.  Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction.

Authors:  Leanne M Cotton; Moira K O'Bryan; Barry T Hinton
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

Review 3.  Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control.

Authors:  B Shannan; M Seifert; D A Boothman; W Tilgen; J Reichrath
Journal:  J Mol Histol       Date:  2006-09-19       Impact factor: 2.611

Review 4.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

5.  A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.

Authors:  Alena Y Edwards; Anna Elgart; Colm Farrell; Ofra Barnett-Griness; Laura Rabinovich-Guilatt; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2017-05-02       Impact factor: 4.335

Review 6.  Exploring the Role of CLU in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Mst Marium Begum; Md Siddiqul Islam; Tapan Behl; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2020-08-21       Impact factor: 3.911

7.  Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.

Authors:  Sahar M Hazzaa; Osama M Elashry; Ibtesam K Afifi
Journal:  Pathol Oncol Res       Date:  2009-09-09       Impact factor: 3.201

Review 8.  Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.

Authors:  Sohaib Al-Asaaed; Eric Winquist
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Authors:  Adriana Aguilar-Mahecha; Christiane Cantin; Maureen O'Connor-McCourt; Andre Nantel; Mark Basik
Journal:  Proteome Sci       Date:  2009-04-06       Impact factor: 2.480

Review 10.  Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?

Authors:  Charles J Rosser; Micah Gaar; Stacy Porvasnik
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.